KalVista (KALV) Form 3 — No Securities Reported by COO on 10/06/2025
Rhea-AI Filing Summary
Arif Bilal, listed as Chief Operations Officer and a director of KalVista Pharmaceuticals, Inc. (KALV), filed an initial Form 3 reporting that no securities are beneficially owned as of the event date 10/06/2025. The filing was signed by an attorney-in-fact on 10/08/2025. This Form 3 records a disclosure obligation under Section 16; instead of listing share ownership or derivative positions, it indicates the reporting person currently holds zero reportable equity or derivative interests.
Positive
- Compliance obligation met with an initial Form 3 filing
- Clear disclosure that no reportable securities are owned as of 10/06/2025
Negative
- None.
Insights
TL;DR: Senior officer and director reports no beneficial ownership of company securities.
The filing shows the Chief Operations Officer and director submitted an initial ownership statement that lists no securities directly or indirectly owned as of 10/06/2025. For governance transparency, a Form 3 is required when a person becomes an officer/director; the absence of holdings is an explicit disclosure rather than an omission.
This creates a clear baseline for future Section 16 reporting; any future acquisition, disposals, or derivative grants will generate subsequent Form 4 or Form 5 filings to track insider activity. Investors and compliance teams will monitor filings occurring shortly after onboarding or compensation events to see if equity grants or purchases are reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.